Stay up to date with the latest developments in therapeutics by reading the world’s most respected source of authoritative drug information. For over 40 years Drugs has been the definitive journal of drugs and therapeutics, promoting optimum pharmacotherapy by publishing reviews and original research authored by leading international clinicians and researchers to support clinical decision-making.

Through a rigorous and comprehensive program of peer-reviewed evaluations, Drugs provides detailed and objective analysis covering the full spectrum of new and established drug therapies in all disease areas.

Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

There are no publication charges for standard publishing in Drugs; the journal offers the option of Open Access publication via Springer Open Choice (article processing charge €3,060 / US$3,860). Please click on the link below under ‘Publishing model’ for further information about this service.

Journal information

Editor
  • Dene Peters
Publishing model
Hybrid. Open Access options available

Journal metrics

4.993 (2018)
Impact factor
4.647 (2018)
Five year impact factor
25 days
Submission to first decision
103 days
Submission to acceptance
509,725 (2019)
Downloads

Latest articles

About this journal

Electronic ISSN
1179-1950
Print ISSN
0012-6667
Abstracted and indexed in
  1. BIOSIS
  2. CAB Abstracts
  3. CNKI
  4. Chemical Abstracts Service (CAS)
  5. Current Contents/ Life Sciences
  6. Current Contents/Clinical Medicine
  7. EBSCO Academic Search
  8. EBSCO Advanced Placement Source
  9. EBSCO Biomedical Reference Collection
  10. EBSCO CINAHL
  11. EBSCO Discovery Service
  12. EBSCO Nursing and Allied Health Collection
  13. EBSCO Rehabilitation & Sports Medicine Source
  14. EBSCO SPORTDiscus
  15. EBSCO STM Source
  16. EBSCO Science & Technology Collection
  17. EMBASE
  18. EMBiology
  19. EMCare
  20. Elsevier Biobase
  21. Google Scholar
  22. Institute of Scientific and Technical Information of China
  23. Japanese Science and Technology Agency (JST)
  24. Journal Citation Reports/Science Edition
  25. Medline
  26. Naver
  27. OCLC WorldCat Discovery Service
  28. Pathway Studio
  29. ProQuest Agricultural & Environmental Science Database
  30. ProQuest Biological Science Database
  31. ProQuest Biotechnology Research Abstracts
  32. ProQuest British Nursing Database
  33. ProQuest Central
  34. ProQuest Engineering
  35. ProQuest Environmental Science
  36. ProQuest Health & Medical Collection
  37. ProQuest Health Research Premium Collection
  38. ProQuest Materials Science and Engineering Database
  39. ProQuest Medical Database
  40. ProQuest Natural Science Collection
  41. ProQuest Neurosciences Abstracts
  42. ProQuest Nursing & Allied Health Database
  43. ProQuest SciTech Premium Collection
  44. ProQuest Technology Collection
  45. ProQuest Toxicology Abstracts
  46. ProQuest Virology and AIDS Abstracts
  47. ProQuest-ExLibris Primo
  48. ProQuest-ExLibris Summon
  49. Psyndex
  50. Reaxys
  51. SCImago
  52. SCOPUS
  53. Science Citation Index Expanded (SciSearch)
  54. Semantic Scholar
Copyright information

Rights and permissions

Springer policies

© Springer Nature Switzerland AG